Company intelligence / Profile preview

Conduit Collab

Naples, Florida, United Statesconduitcollab.com ↗

Ownership: Private
Development stage: Other

Overview

Conduit Pharmaceuticals acquires Phase II-ready small molecule assets from major pharma companies. It advances these through clinical proof-of-concept using a proprietary AI-driven platform focused on efficient trial design, formulation innovation, and rapid go/no-go decisions. The lead program targets lupus with a glucokinase inhibitor; preclinical data are expected Q2 2025. The business model centers on outlicensing after successful early clinical validation rather than full regulatory approval.

Therapeutic areas: Immunology
Modalities: Small moleculeProprietary solid oral dosage forms
Industry: Biotech

Partnerships

Sarborg LimitedAgility Life SciencesCharles River Laboratories

Beyond the preview

Go deeper on Conduit Collab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Conduit Collab.

Explore the full profile